Skip to main content
. 2020 Dec 11;6(2):92–105. doi: 10.1016/S2468-1253(20)30333-2

Table 3.

Histopathological tumour characteristics

Randomised patients
Non-randomised patients
Organ preservation (n=27) Radical surgery (n=28) Organ preservation (n=61) Radical surgery(n=7)
TNM (y)pT stage
0 7 (26%) 0 20 (33%) 0
1 6 (22%) 14 (50%) 18 (30%) 1 (14%)
2 8 (30%) 13 (46%) 12 (20%) 6 (86%)
3 5 (19%) 1 (4%) 4 (7%) 0
x 0 0 1 (2%) 0
Clinical complete response with no surgery 1 (4%) 0 5 (8%) 0
All cases with a complete response 8 (30%) 0 25 (41%) 0
Kikuchi substaging of pT1 tumours
Submucosal tumour stage 1 2 (33%) 2 (14%) 7 (39%) 0
Submucosal tumour stage 2 1 (17%) 3 (21%) 6 (33%) 0
Submucosal tumour stage 3 3 (50%) 9 (64%) 5 (38%) 1 (100%)
TNM pN stage
0 3 (11%) 23 (82%) 0 7 (100%)
1 0 3 (10%) 0 0
2 0 1 (4%) 0 0
x 24 (89%) 1 (4%) 60 (100%) 0
Surgical resection margin <1 mm
Clear 23 (85%) 26 (93%) 49 (82%) 7 (100%)
Involved adenoma 0 1 (4%) 1 (2%) 0
Involved carcinoma (deep) 3 (11%) 1 (4%) 1 (2%) 0
Involved carcinoma (mucosal) 0 0 0 0
No surgery 1 (4%) 0 5 (8%) 0
Missing 0 0 4 (6%) 0
Positive lymphatic invasion 0 5 (18%) 1 (2%) 1 (14%)
Positive vascular invasion 2 (8%) 7 (25%) 4 (7%) 0
Tumour differentiation
Well or moderately differentiated 17 (63%) 26 (93%) 31 (51%) 7 (100%)
Poorly differentiated 2 (7%) 2 (7%) 3 (5%) 0
Pathological complete response 7 (26%) 0 19 (31%) 0
Complete response* 1 (4%) 0 5 (8%) 0
Tumour diameter, mm 3 (0–17) 10 (0–30) 4 (0–45) 8 (2–30)
Radiotherapy response (Dworak 5-point system)
Complete 7 (26%) 0 19 (31%) ··
Good 5 (19%) 2 (67%) 15 (25%) ··
Moderate 6 (22%) 0 7 (11%) ··
Mild 4 (15%) 0 4 (7%) ··
No surgery 1 (4%) 0 5 (8%) ··
Missing 3 (11%) 1 (33%) 5 (8%) ··
High-risk histopathological feature present 16/27 (59%) 24/28 (86%) 24/61 (39%) 7/7 (100%)
*

Including pathological and clinical complete response.

Comparison of proportion of randomised patients with one or more histopathological feature considered high risk for relapse following local excision (maximum tumour diameter >30 mm, R1 resection, predominantly poor differentiation, presence of lymphatic or venous invasion and depth of invasion ≥submucosal tumour stage 3; p=0·03, χ2 test).